^
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
CPEB1 underexpression
Gastric Adenocarcinoma
5-fluorouracil
Sensitive
:
C3
J Gastrointest Oncol - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
KN046 + KN026
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
KN046 + KN026
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CEACAM5 overexpression
Gastric Cancer
SAR408701
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
nivolumab + regorafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + LAG3 overexpression
Gastric Cancer
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + CTLA4 overexpression
Gastric Cancer
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastric Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR expression + HER-2 expression
Gastric Cancer
ASLAN001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastric Cancer
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive
:
A1
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab-anns
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-pkrb
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
trastuzumab-pkrb
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastric Cancer
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastric Cancer
ramucirumab
Sensitive
:
A1
No biomarker
Gastric Cancer
capecitabine
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive
:
A1